Cingulate Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Cingulate wird ein Gewinn- und Umsatzwachstum von 65.6% bzw. 58.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 73.9% pro Jahr wachsen soll.

Wichtige Informationen

65.6%

Wachstumsrate der Gewinne

73.9%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	27.6%
Wachstumsrate der Einnahmen	58.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	10 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're A Bit Worried About Cingulate's (NASDAQ:CING) Cash Burn Situation

Aug 26

Cingulate Q2 GAAP EPS of -$0.36

Aug 11

Is Cingulate (NASDAQ:CING) In A Good Position To Deliver On Growth Plans?

Apr 04

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:CING - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	19	5	N/A	N/A	1
12/31/2025	N/A	-14	N/A	-15	2
12/31/2024	N/A	-11	N/A	-12	4
3/31/2024	N/A	-23	-20	-20	N/A
12/31/2023	N/A	-24	-15	-15	N/A
9/30/2023	N/A	-21	-17	-17	N/A
6/30/2023	N/A	-19	-16	-16	N/A
3/31/2023	N/A	-17	-16	-16	N/A
12/31/2022	N/A	-18	-16	-16	N/A
9/30/2022	N/A	-16	-17	-16	N/A
6/30/2022	N/A	-27	-16	-15	N/A
3/31/2022	N/A	-24	-13	-13	N/A
12/31/2021	N/A	-21	-11	-10	N/A
9/30/2021	N/A	-19	-8	-8	N/A
6/30/2021	N/A	-5	-7	-7	N/A
3/31/2021	N/A	-6	-7	-7	N/A
12/31/2020	N/A	-7	-7	-7	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CING wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: CING wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: CING wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: CING wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: CING wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CING in 3 Jahren voraussichtlich hoch sein wird

Cingulate Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast to breakeven in 2025

No longer forecast to breakeven

Recent updates

Cingulate Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2) for Continued Listing on The Nasdaq Capital Market

Cingulate Inc., Annual General Meeting, Jun 11, 2024

Cingulate Inc. Regains Compliance with the Board Composition Requirements of Nasdaq Set in Nasdaq Listing Rule 5605

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to Its Board of Directors

Cingulate Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.

Cingulate Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.

Cingulate Inc. Announces Promotion of Jennifer Callahan as Chief Financial Officer

Cingulate Inc. has filed a Follow-on Equity Offering in the amount of $26 million.

Cingulate Receives Non-Compliance Notice from Nasdaq

Cingulate Inc. and Cingulate Therapeutics LLC Announce Resignation of Officer

Scott Applebaum Provides Cingulate Inc. with Notice of His Resignation from the Board of Directors

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTX-2103 (Buspirone)

Cingulate Inc. has filed a Follow-on Equity Offering.

The Listing Qualifications Staff of The Nasdaq Stock Market LLC Determines to Delist Cingulate's Securities from Nasdaq Unless it Timely Requests Hearing Before the Nasdaq Hearings Panel

Cingulate Inc. to Host CNS Key Opinion Leader Panel in New York City Expert Analysis of Cingulate, it’s Phase 3 ADHD Adult Data, Anxiety, and PTR™ Drug Delivery Platform Innovations

Cingulate Weighs Reverse Stock Split to Avoid Delisting

Cingulate Inc. has completed a Follow-on Equity Offering in the amount of $4 million.

New major risk - Shareholder dilution

New major risk - Negative shareholders equity

Cingulate Inc. Receives A Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Cingulate Inc. Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (Dexmethylphenidate) for Adhd

Cingulate Inc. Successfully Manufactures Clinical Supply Initiation of Pediatric Phase 3 Studies to Commence in July and August

New major risk - Market cap size

Cingulate Completes Phase 3 Adult Trial of Ctx-1301 (Dexmethylphenidate) for Adhd

Cingulate Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement

Cingulate Inc., Annual General Meeting, Jun 15, 2023

Forecast to breakeven in 2025

No longer forecast to breakeven

Cingulate Inc. Announces Resignation of Jeff Conroy from the Board of Directors

Cingulate Inc. Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD

Independent Director recently bought US$75k worth of stock

Cingulate Inc. Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD

Cingulate Inc. Provides Clinical Update

Cingulate Inc. Announces the Resignation of Jeff Hargroves from the Board of Directors

Cingulate Presents Data for its Triple-Release Buspirone Product Candidate: CTx-2103

Here's Why We're A Bit Worried About Cingulate's (NASDAQ:CING) Cash Burn Situation

Cingulate Inc. Appoints Scott Applebaum as Class III Director

Cingulate Q2 GAAP EPS of -$0.36

Cingulate Inc. Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders

Cingulate Inc. Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders

Cingulate Inc. Announces First Subject Dosing in its Human Formulation Study of CTX-2103 (Buspirone) for the Treatment of Anxiety

Cingulate Inc., Annual General Meeting, Jun 08, 2022

Is Cingulate (NASDAQ:CING) In A Good Position To Deliver On Growth Plans?

Independent Director recently bought US$89k worth of stock

Cingulate Inc Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for Attention Deficit/Hyperactivity Disorder (ADHD)

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken